Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors, Virtual, United States (21/09/2021–21/09/2021) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 1 European CME credit (ECMEC®). Specialists should claim only those hours of credit that are commensurate with their participation in the activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the conversion process can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities occurring outside of Canada that are recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1), as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation in the event once he/she has completed the feedback form. See criteria 9 and 23 of UEMS 2016.20.
In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day: 21.09.2021 - 1.00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME, with a maximum of 8 ECMEC®s per day. See Chapter X of UEMS 2016.20.
Acknowledgment of Support
This activity is supported by educational grants from Daiichi Sankyo.
Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors
Release Date: October 14, 2021
Expiration Date: October 14, 2022
Activity Overview
This educational activity is an archive of a live virtual symposium held on September 21, 2021.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Daiichi Sankyo.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the mechanistic rationale concerning the role of ADCs in solid tumors
- Implement best practices for HER2 diagnostic testing to facilitate molecular characterization and selection of HER2-directed therapies in patients with solid tumors
- Describe ongoing clinical trials and emerging efficacy and safety trial data on the application of novel ADCs in the treatment of patients with solid tumors
- Formulate strategies to integrate novel ADC approaches into clinical practice for the treatment of patients with solid tumors
Faculty, Staff, and Plannrs’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
Program Chair
Head, Breast Cancer Unit
Medical Oncology Service
Vall d’Hebron University Hospital
Barcelona, Spain
Disclosures: Consultant: Puma Biotechnology, F. Hoffmann-La Roche & Co., Pfizer Inc.
Faculty
Associate Professor Chief, Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center New York, NY
Disclosures: Grant/Research Support: NCI, Department of Defense, Cycle for Survival, Fred's Team, Rgenix, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, Merck. Consultant: Bristol Myers Squibb, Merck Serono, Rgenix, Eli Lilly and Company, Daiichi Sankyo, Pfizer, Bayer, Imugene Ltd., Merck & Co., Zymeworks Inc., Seattle Genetics, Basilea Pharmaceutica AG Pharma, AstraZeneca. Shareholder: Rgenix (stock options).
Head of Thoracic Oncology Program
Léon Bérard Cancer Centre
Lyon, France
Disclosures: Grant/Research Support: Roche, AstraZeneca, Takeda, Boehringer Ingelheim, Chugai. Consultant: F. Hoffmann-La Roche & Co., Eli Lilly and Company, Pfizer, Boehringer Ingelheim, Clovis Oncology, Merck Sharp & Dohme, Bristol Myers Squibb, Novartis Pharmaceuticals, Pierre Fabre, AstraZeneca, Takeda, Sanofi Genzyme, Gritstone Bio, GlaxoSmithKline. Speaker’s Bureau: Eli Lilly and Company, F. Hoffmann-La Roche & Co., AstraZeneca, Pfizer Inc., Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, MSD, Takeda, Novartis Pharmaceuticals, Illumina, Inc., Chugai Pharma USA, Inc. Travel: F. Hoffmann-La Roche & Co., AstraZeneca, Pfizer Inc., Takeda.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
